These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 38232115)
1. CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma. Wang G; Fu J; Liu M; Zheng Q PLoS One; 2024; 19(1):e0277872. PubMed ID: 38232115 [TBL] [Abstract][Full Text] [Related]
2. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma. Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290 [TBL] [Abstract][Full Text] [Related]
3. Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma. Huang J; Chen Z; Ding C; Lin S; Wan D; Ren K Front Oncol; 2021; 11():711402. PubMed ID: 34497764 [TBL] [Abstract][Full Text] [Related]
4. Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118 [TBL] [Abstract][Full Text] [Related]
5. A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets in Uterine Corpus Endometrial cancer. Lei P; Wang H; Yu L; Xu C; Sun H; Lyu Y; Li L; Zhang DL Int Immunopharmacol; 2022 Jul; 108():108743. PubMed ID: 35413679 [TBL] [Abstract][Full Text] [Related]
6. Solute Carrier Family 7 Member 11 (SLC7A11) is a Potential Prognostic Biomarker in Uterine Corpus Endometrial Carcinoma. Fang X; Zhang T; Chen Z Int J Gen Med; 2023; 16():481-497. PubMed ID: 36777097 [TBL] [Abstract][Full Text] [Related]
7. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma. Wang Z; Xing L; Huang Y; Han P Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126 [TBL] [Abstract][Full Text] [Related]
8. Investigating novel biomarkers in uterine corpus endometrial carcinoma: in silico analysis and clinical specimens validation via RT-qPCR and immunohistochemistry. Li J; Ramzan F; Zhong G Am J Cancer Res; 2023; 13(9):4376-4400. PubMed ID: 37818076 [TBL] [Abstract][Full Text] [Related]
9. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Zhang X; Wang Y; A G; Qu C; Chen J Front Immunol; 2021; 12():721030. PubMed ID: 34531868 [TBL] [Abstract][Full Text] [Related]
10. MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma. Chen J; Wu S; Wang J; Han C; Zhao L; He K; Jia Y; Cui M J Cell Mol Med; 2023 Jun; 27(12):1708-1724. PubMed ID: 37246638 [TBL] [Abstract][Full Text] [Related]
11. Significance analysis of PAX8 expression in endometrial carcinoma. Hu S; Gan H; Yang F Medicine (Baltimore); 2022 Oct; 101(42):e31159. PubMed ID: 36281161 [TBL] [Abstract][Full Text] [Related]
12. CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma. Lin T; Zhang E; Mai PP; Zhang YZ; Chen X; Peng LS Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34085699 [TBL] [Abstract][Full Text] [Related]
13. m Fang F; Wang P; Huang H; Ye M; Liu X; Li Q BMC Cancer; 2022 Dec; 22(1):1364. PubMed ID: 36581816 [TBL] [Abstract][Full Text] [Related]
14. Positive Correlation Between LTA Expression and Overall Immune Activity Suggests an Increased Probability of Survival in Uterine Corpus Endometrial Carcinoma. Shi M; Luo F; Shao T; Zhang H; Yang T; Wei Y; Chen R; Guo R Front Cell Dev Biol; 2021; 9():793793. PubMed ID: 35155447 [TBL] [Abstract][Full Text] [Related]
15. SPC25 Functions as a Prognostic-Related Biomarker, and Its High Expression Correlates with Tumor Immune Infiltration and UCEC Progression. Liao LX; Zhang M; Xu X; Zhang S; Guo YZ Front Biosci (Landmark Ed); 2024 Feb; 29(2):69. PubMed ID: 38420826 [TBL] [Abstract][Full Text] [Related]
16. RNA modification regulator DDC in endometrial cancer affects the tumor microenvironment and patient prognosis. Zhao H; Shi C; Zhao G; Liu J; Wang X; Liang J; Li F Sci Rep; 2023 Oct; 13(1):18057. PubMed ID: 37872211 [TBL] [Abstract][Full Text] [Related]
17. Exploration of prognostic biomarkers and therapeutic targets in the microenvironment of bladder cancer based on CXC chemokines. Sun X; Chen Q; Zhang L; Chen J; Zhang X Math Biosci Eng; 2021 Jul; 18(5):6262-6287. PubMed ID: 34517533 [TBL] [Abstract][Full Text] [Related]
18. A novel risk prediction model of pyroptosis-related genes for the prognosis and immunotherapy response of endometrial cancer. Liu ZS; Jing CL Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2259-2278. PubMed ID: 35442481 [TBL] [Abstract][Full Text] [Related]
19. Alteration of tumor associated neutrophils by PIK3CA expression in endometrial carcinoma from TCGA data. Pan Y; Jia LP; Liu Y; Han Y; Deng Q J Ovarian Res; 2019 Aug; 12(1):81. PubMed ID: 31472672 [TBL] [Abstract][Full Text] [Related]
20. Relationship between Prognosis, Immune Infiltration Level, and Differential Expression of PARVG Gene in Uterine Corpus Endometrial Carcinoma. Wang F; Bi J; Yi C; Zhang Y; Zhang Y; Yue Q Contrast Media Mol Imaging; 2022; 2022():7376588. PubMed ID: 35655721 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]